



Meta-Analysis Working Group REPORT to GA Chicago June 2018

Chair: Ros Glasspool (SGCTG) Co Chair: Xavier Paoletti (GINECO)

ONGOING TRIALS

Trial Name	Trial Description	# pts enrolled/total	Lead Group/Contact person
SEPOC	<p>Surrogate Endpoints in Ovarian Cancer Pilot project for the MA group Primary objective: to assess surrogate endpoints for OS of</p> <ul style="list-style-type: none"> • Progression free survival defined as per GCIG criteria and by RECIST alone • Overall response using RECIST v1.1 <p>Study CA-125 evolution as a surrogate endpoint of PFS</p> <p>Secondary projects Kelim validation Prognostic / predictive factors Histology (50% of serous hist.) Elderlies Platinum and paclitaxel schedule (request network meta-analysis)</p>	<p>10 500 patients 16 trials</p> <p>EORTC DoCaCel CCTG MRC HECOG SGCTG MITO JGOG NSGO MANGO CCTG MITO GINECO SGCTG JGOG ERASMUS 6 further trials in discussion/review GOG</p>	GINECO/SGCTG Xavier Paoletti/Ros Glasspool

ONGOING TRIALS

Trial Name	Trial Description	# pts enrolled/total	Lead Group/Contact person
<p>PFS benefit with PARPi maintenance therapy in ovarian cancer</p>	<p>Aim To investigate subgroups, defined by clinical and pathologic characteristics, that could predict greater PFS benefit with PARP maintenance therapy in both germline, somatic BRCA and non-BRCA ovarian cancer patient populations</p> <p>Subgroups: Age Time to progression with penultimate platinum: Response to last platinum: Number of previous platinum regimens Prior bevacizumab therapy: BRCA: BRCA 1 vs BRCA2 vs somatic BRCA</p>	<p>Trials to be included <u>Study 19</u> <u>SOLO2</u> ARIEL 3 agreed NOVA (awaiting TSC decision)</p>	<p>ANZGOG/Chee Lee</p>



Meta-Analysis Group

Possibilities



Tumour sites

Ovarian Carcinoma

- Surrogate endpoints in relapsed disease
- Treatment effects in relapsed disease

- Endometrial carcinoma

- Adjuvant treatment

- Cervical carcinoma

- Chemotherapy in first line treatment

- Rare Tumours

Molecular sub groups

ANZGOG: published data meta-analysis benefit of PARPi maintenance in women with somatic BRCA mutations

Translational Projects

Potential for the GCIG to add value to work of the individual groups

- Expertise
- Independent, secure space with established TOR and authorship rules

Meta-Analysis Group

To Make it Work



- Expectation that GCIIG badged trials will be made available for meta-analysis projects
- Stream line processes for applying for data
 - Groups to establish or review their process for doing this
- Committees to actively and prospectively plan projects
- Continue work of Harmonisation group to standardise data variables
- Use the pathology manuals with standardised criteria being developed by the pathology group